A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

Inclusion Criteria: * Patients aged between 7 and 15 years * Patients giving assent and whose legal guardian giving informed consent * Outpatients * Patients diagnosed as atopic dermatitis * Patients who require the treatment with topical corticosteroid on areas other than face, head and neck * Patients whose diaries can be properly maintained * Patients who have 2 grades or more pruritus score Exclusion Criteria: * Patients with bronchial asthma who require concomitant use of the corticosteroid * Patients who have been undergoing specific desensitization therapy or nonspecific immunomodulation therapy or phototherapy * Patients with current or previous history of drug hypersensitivity * Patients who have been treated with Bepotastine besilate in the past * Patients who have; a skin infection, or with zooparasite such as scabies and pediculosis; eczematous otitis externa with perforation in the eardrum; dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2; on areas where topical corticosteroid is applied * Patients who have spastic disease such as epilepsy * Patients who concurrently have renal function abnormalities that may cause safety problems * Patients who do not give consent to use birth control * Pregnant patients, at risk of pregnancy or breastfeeding * Patients who had participated in any clinical trial in the last 12 weeks